13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

(iv)

Farallon Partners, L.L.C., a Delaware limited liability company (the “Farallon General Partner“), which is the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, with respect to the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by FCIP XR as a Farallon Akubra Fund, the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by each of FCP XR and FCIP III as Farallon Bushranger Funds, and the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by each of FCOI II SS and FCIP II as Farallon Ute Funds.

(v)

NGP, L.L.C., a Delaware limited liability company (the “NSSP General Partner“), which is the general partner of NSSP, with respect to the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by NSSP as a Farallon Akubra Fund.

(vi)

Farallon Capital Management, L.L.C., a Delaware limited liability company (the “Management Company“), the manager of the NSSP General Partner, with respect to the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by NSSP as a Farallon Akubra Fund.

(vii)

Farallon AA GP, L.L.C., a Delaware limited liability company (the “FCAAI General Partner“), which is the general partner of FCAAI, with respect to the Ordinary Shares indirectly held (and indirectly acquirable upon the exercise of Warrants) by FCAAI as a Farallon Bushranger Fund.

(viii)

Farallon Partners GP VI, L.L.C., a Delaware limited liability company ( the “FSSP VI General Partner“), which is the general partner of FSSP VI, with